Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

Journal of Immune Based Therapies and Vaccines

Volumn 9, Issue , 2011, Pages

  Butov, Dmitry A ^a   Pashkov, Yuri N ^a   Stepanenko, Anna L ^a   Choporova, Aleksandra I ^a   Butova, Tanya S ^a   Batdelger, Dendev ^b   Jirathitikal, Vichai ^c   Bourinbaiar, Aldar S ^d   Zaitzeva, Svetlana I ^a  

^a KHARKIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b National Research Center for Infectious Diseases NRCID   (Mongolia)

^c Bangpakong Industrial Park ^*  (Thailand)

^d Immunitor USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIKACIN; AMINOSALICYLIC ACID; BILIRUBIN; CAPREOMYCIN; CILASTATIN; CYCLOSERINE; ETHAMBUTOL; GATIFLOXACIN; HEMOGLOBIN; ISONIAZID; METRONIDAZOLE; OFLOXACIN; PLACEBO; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; V5 VACCINE;

ADULT; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOTHERAPY; INFECTION PREVENTION; LEUKOCYTE COUNT; LIVER FUNCTION; LIVER SIZE; LYMPHOCYTE COUNT; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PHASE 2 CLINICAL TRIAL; RELAPSE; SPUTUM SMEAR;

EID: 78651431160     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-9-3     Document Type: Article

References (36)

1. Feshchenko Y, Melnyk VM, Novozhilova IO, Lyrnyk SV. The mortality of patients with tuberculosis: structure, dynamics and peculiarities in epidemic period. Ukr Pulmonol J 2009, 3:5-9.
2. Nikolayevskyy VV, Brown TJ, Bazhora YI, Asmolov AA, Balabanova YM, Drobniewski FA. Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine. Clin Microbiol Infect 2007, 13:129-138. 10.1111/j.1469-0691.2006.01583.x, 17328724.
3. Atun R, Olynik I. Resistance to implementing policy change: the case of Ukraine. Bulletin of World Health Organization 2008, 86:147-154.
4. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route. Lett Drug Design Discovery 2007, 4:540-544.
5. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine 2008, 26:2733-2737. 10.1016/j.vaccine.2008.03.021, 18455842.
6. Batdelger D, Dandii D, Dahgwahdorj Y, Erdenetsogt E, Oyunbileg J, Tsend N, Bayarmagnai B, Jirathitikal V, Bourinbaiar AS. Clinical experience with therapeutic vaccines designed for patients with hepatitis. Curr Pharm Design 2009, 15:1159-1171.
7. Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Frolov VM, Tarakanovskaya MG, Jirathitikal V, Bourinbaiar AS. Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis. J Vaccin Vaccinat 2010, 1:103.
8. Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Frolov VM, Tarakanovskaya MG, Batdelger D, Jirathitikal V, Bourinbaiar AS. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV co-infected TB. Immunotherapy
9. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957, 28:56-63.
10. Ostrovskiǐ VK, Asanov BM, Iangolenko DV. Some blood indices and the leukocytic index of intoxication in tuberculosis, pneumonias, abscesses, and cancer of the lung. Probl Tuberk Bolezn Legk 2005, 3:43-46.
11. Zaitzeva SI, Matveeva SL, Gerasimova TG, Pashkov YN, Butov DA, Pylypchuk VS, Frolov VM, Kutsyna GA. Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo. Clin Microbiol Infect 2009, 15:1154-1162. 10.1111/j.1469-0691.2009.02760.x, 19456829.
12. Veenstra H, Baumann R, Carroll NM, Lukey PT, Kidd M, Beyers N, Bolliger CT, van Helden PD, Walzl G. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin Exp Immunol 2006, 145:252-260. 10.1111/j.1365-2249.2006.03144.x, 1809688, 16879244.
13. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR, . ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952. 10.1164/rccm.200510-1666ST, 17021358, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee.
14. Vasantha M, Gopi PG, Subramani R. Weight gain in patients with tuberculosis treated under directly observed treatment short-course (DOTS). Indian J Tuberc 2009, 56:5-9.
15. Yew WW, Leung CC. Prognostic significance of early weight gain in underweight patients with tuberculosis. Am J Respir Crit Care Med 2006, 174:236-237. 10.1164/rccm.200605-669ED, 16864715.
16. Majumdar A, Kamble PD, Harinath BC. Detection of circulating free and immune-complexed antigen in pulmonary tuberculosis using cocktail of antibodies to Mycobacterium tuberculosis excretory secretory antigens by peroxidase enzyme immunoassay. Indian J Tuberc 2010, 57:67-74.
17. Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J. Double-blind, randomized, placebo-controlled Phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010, 28:1106-1116. 10.1016/j.vaccine.2009.09.134, 19853680.
18. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004, 9:1701-1719. 10.2741/1292, 14977580.
19. Zhao G-R, Feng D-H. A systematic review of inactivated Mycobacterium phlei injection for adjunctive treatment of drug resistant pulmonary tuberculosis. Pharm J Chin PLA 2009, 25:361-364.
20. Nyasulu PS. Role of adjunctive Mycobacterium w immunotherapy for tuberculosis. J Exp Clin Med 2010, 2:123-129.
21. Svistunova AS, Pinegin BV, Selitskaia RP, Arshinova SS, Klimova EG, Andronova TM, Batyrov FA, Simonova AV. The use of immunomodulator likopid in the combined treatment pulmonary tuberculosis. Probl Tuberk 2002, 3:21-25.
22. Lei JP, Xiong GL, Hu QF, Li Y, Zong PL, Tu SH, Tu RY. Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis. Zhonghua Yu Fang Yi Xue Za Zhi 2008, 42:86-89.
23. Kaufmann SH. Is the development of a new tuberculosis vaccine possible?. Nat Med 2000, 6:955-960. 10.1038/79631, 10973302.
24. Kato S, Tokunaga O, Yoshiyama T. Analysis of Koch's phenomenon by BCG vaccination with the multi-puncture method in Japan. Kekkaku 2010, 85:782-785.
25. Repique CJ, Li A, Collins FM, Morris SL. DNA Immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 2002, 70:3318-3323. 10.1128/IAI.70.7.3318-3323.2002, 128037, 12065468.
26. Moreira AL, Tsenova L, Aman MH, Bekker L-G, Freeman S, Mangaliso B, Schröder U, Jagirdar J, Rom WN, Tovey MG, Freedman VH, Kaplan G. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun 2002, 70:2100-2107. 10.1128/IAI.70.4.2100-2107.2002, 127838, 11895976.
27. Basaraba RJ, Izzo AA, Brandt L, Orme IM. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 2006, 24:280-286. 10.1016/j.vaccine.2005.07.103, 16153758.
28. Radaeva TV, Nikonenko BV, Kapina MA, Mishchenko VV, Apt AS. Experimental approaches to designing vaccines against tuberculous infection reactivation. Probl Tuberk Bolezn Legk 2006, 5:45-48.
29. Cruz A, Fraga AG, Fountain JJ, Rangel-Moreno J, Torrado E, Saraiva M, Pereira DR, Randall TD, Pedrosa J, Cooper AM, Castro AG. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010, 207:1609-1616. 10.1084/jem.20100265, 20624887.
30. Derrick SC, Perera LP, Dheenadhayalan V, Yang A, Kolibab K, Morris SL. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis. Vaccine 2008, 26:6092-6098. 10.1016/j.vaccine.2008.09.011, 18809446.
31. Roth AE, Benn CS, Ravn H, Rodrigues A, Lisse IM, Yazdanbakhsh M, Whittle H, Aaby P. Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. BMJ 2010, 340:c671. 10.1136/bmj.c671, 2839082, 20231251.
32. Silin DS, Lyubomska OV, Jirathitikal V, Bourinbaiar AS. Oral vaccination: where we are?. Expert Opin Drug Deliv 2007, 4:323-340. 10.1517/17425247.4.4.323, 17683247.
33. Zaitzeva SI, Matveeva SL, Gerasimova TG, Pashkov Y, Butov DA, Pylypchuk VS, Frolov VM, Kutsyna GA. Efficacy and safety of phytoconcentrate Dzherelo (Immunoxel) in treatment of patients with multi-drug resistant TB (MDR-TB) in comparison to standard chemotherapy. Res J Med Sci 2009, 3:36-41.
34. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 2009, 30:769-782. 10.1016/j.ccm.2009.08.009, 19925966.
35. Thaiss CA, Kaufmann SH. Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J Biol Med 2010, 83:209-215. 3002148, 21165340.
36. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology 2010, 15:433-450. 10.1111/j.1440-1843.2010.01739.x, 20415982.